Table 2 The baseline characteristics of spCRC patients survived or dead
From: Second primary colorectal cancer in adults: a SEER analysis of incidence and outcomes
| Â | Â | Groups | Â | Â | |
|---|---|---|---|---|---|
Variables | Total (n = 4680) | Survived (n = 2246) | Dead group (n = 2434) | Statistics | P |
Age, Mean ± SD | 66.24 ± 12.76 | 64.33 ± 12.57 | 67.99 ± 12.68 | t = -9.91 |  < 0.001 |
Sex, n(%) |  |  |  | χ2 = 0.771 | 0.380 |
 Female | 2061 (44.04) | 1004 (44.70) | 1057 (43.43) |  |  |
 Male | 2619 (55.96) | 1242 (55.30) | 1377 (56.57) |  |  |
Race, n (%) |  |  |  | χ2 = 11.400 | 0.003 |
 Black | 564 (12.05) | 253 (11.26) | 311 (12.78) |  |  |
 Unknown | 474 (10.13) | 260 (11.58) | 214 (8.79) |  |  |
 White | 3642 (77.82) | 1733 (77.16) | 1909 (78.43) |  |  |
Insurance, n (%) |  |  |  | χ2 = 101.191 |  < 0.001 |
 Any Medicaid | 410 (8.76) | 207 (9.22) | 203 (8.34) |  |  |
 Blank | 1694 (36.20) | 650 (28.94) | 1044 (42.89) |  |  |
 Insured | 1930 (41.24) | 1052 (46.84) | 878 (36.07) |  |  |
 Insured/No specifics | 539 (11.52) | 281 (12.51) | 258 (10.60) |  |  |
 Uninsured | 107 (2.29) | 56 (2.49) | 51 (2.10) |  |  |
Histology, n (%) |  |  |  | χ2 = 25.108 |  < 0.001 |
 Adenocarcinoma | 3320 (70.94) | 1543 (68.70) | 1777 (73.01) |  |  |
 Mucous adenocarcinoma | 377 (8.06) | 181 (8.06) | 196 (8.05) |  |  |
 Signet ring cell carcinoma | 60 (1.28) | 19 (0.85) | 41 (1.68) |  |  |
 Others | 923 (19.72) | 503 (22.40) | 420 (17.26) |  |  |
Grade, n (%) |  |  |  | χ2 = 16.618 |  < 0.001 |
 Grade I/Grade II | 3250 (69.44) | 1598 (71.15) | 1652 (67.87) |  |  |
 Grade III/Grade IV | 761 (16.26) | 314 (13.98) | 447 (18.36) |  |  |
 Unknown | 669 (14.29) | 334 (14.87) | 335 (13.76) |  |  |
T stage, n (%) |  |  |  | χ2 = 76.008 |  < 0.001 |
 T2 | 1430 (30.56) | 798 (35.53) | 632 (25.97) |  |  |
 T3 | 2057 (43.95) | 926 (41.23) | 1131 (46.47) |  |  |
 T4 | 588 (12.56) | 214 (9.53) | 374 (15.37) |  |  |
 Unknown | 605 (12.93) | 308 (13.71) | 297 (12.20) |  |  |
N stage, n (%) |  |  |  | χ2 = 80.725 |  < 0.001 |
 N0 | 2871 (61.35) | 1501 (66.83) | 1370 (56.29) |  |  |
 N1 | 881 (18.82) | 363 (16.16) | 518 (21.28) |  |  |
 N2 | 519 (11.09) | 176 (7.84) | 343 (14.09) |  |  |
 N3 | 7 (0.15) | 3 (0.13) | 4 (0.16) |  |  |
 Unknown | 402 (8.59) | 203 (9.04) | 199 (8.18) |  |  |
M stage, n (%) |  |  |  | χ2 = 71.790 |  < 0.001 |
 M0 | 3982 (85.09) | 1964 (87.44) | 2018 (82.91) |  |  |
 M1 | 339 (7.24) | 89 (3.96) | 250 (10.27) |  |  |
 Unknown | 359 (7.67) | 193 (8.59) | 166 (6.82) |  |  |
AJCC stage, n (%) |  |  |  | χ2 = 129.666 |  < 0.001 |
 I | 1247 (26.65) | 716 (31.88) | 531 (21.82) |  |  |
 II | 1396 (29.83) | 686 (30.54) | 710 (29.17) |  |  |
 III | 1150 (24.57) | 465 (20.70) | 685 (28.14) |  |  |
 IV | 360 (7.69) | 103 (4.59) | 257 (10.56) |  |  |
 Unknown | 527 (11.26) | 276 (12.29) | 251 (10.31) |  |  |
Radiation, n (%) |  |  |  | χ2 = 12.997 |  < 0.001 |
 No/Unknown | 4095 (87.50) | 2006 (89.31) | 2089 (85.83) |  |  |
 Yes | 585 (12.50) | 240 (10.69) | 345 (14.17) |  |  |
Chemotherapy, n (%) |  |  |  | χ2 = 20.350 |  < 0.001 |
 No/Unknown | 2990 (63.89) | 1509 (67.19) | 1481 (60.85) |  |  |
 Yes | 1690 (36.11) | 737 (32.81) | 953 (39.15) |  |  |
Radiation sequence, n (%) | Â | Â | Â | - | 0.004 |
 Only one | 4217 (90.11) | 2044 (91.01) | 2173 (89.28) |  |  |
 After surgery | 261 (5.58) | 98 (4.36) | 163 (6.70) |  |  |
 Before surgery | 192 (4.10) | 97 (4.32) | 95 (3.90) |  |  |
 Both | 6 (0.13) | 4 (0.18) | 2 (0.08) |  |  |
 unknown | 4 (0.09) | 3 (0.13) | 1 (0.04) |  |  |